share_log

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

独家报道:SAB BioTreateutics告诉Benzinga SAB重点介绍了用于季节性和大流行性流感的SAB-176和用于新冠肺炎的SAB-185的数据,显示出对与呼吸系统疾病相关的高度变异病毒的广泛疗效
Benzinga Real-time News ·  2022/11/03 08:41

EXCLUSIVE: SAB Biotherapeutics Tells Benzinga SAB Highlights Data On SAB-176 For Seasonal And Pandemic Influenza And SAB-185 For COVID-19, Showing Broad Efficacy Against Highly Mutating Viruses Associated With Respiratory Disease

独家报道:SAB BioTreateutics告诉Benzinga SAB重点介绍了用于季节性和大流行性流感的SAB-176和用于新冠肺炎的SAB-185的数据,显示出对与呼吸系统疾病相关的高度变异病毒的广泛疗效

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发